TWI350185B - Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one salts and tablets made therefrom - Google Patents

Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one salts and tablets made therefrom

Info

Publication number: TWI350185B
Authority: TW; Taiwan
Prior art keywords: phenyl; decan; diaza; spiro; trifluoromethyl
Prior art date: 2007-03-22

Application number

TW097109944A

Other languages

English (en)

Other versions

TW200902087A (en

Inventor

Zhihui Qiu

Wing-Kee Philip Cho

Na Zhao

Victor Ming-She Wong

Original Assignee

Opko Health Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-22

Filing date

2008-03-20

Publication date

2011-10-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39541515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI350185(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-03-20 Application filed by Opko Health Inc filed Critical Opko Health Inc

2009-01-16 Publication of TW200902087A publication Critical patent/TW200902087A/zh

2011-10-11 Application granted granted Critical

2011-10-11 Publication of TWI350185B publication Critical patent/TWI350185B/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TW097109944A 2007-03-22 2008-03-20 Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one salts and tablets made therefrom TWI350185B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US91950107P	2007-03-22	2007-03-22

Publications (2)

Publication Number	Publication Date
TW200902087A TW200902087A (en)	2009-01-16
TWI350185B true TWI350185B (en)	2011-10-11

Family

ID=39541515

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW097109944A TWI350185B (en)	2007-03-22	2008-03-20	Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one salts and tablets made therefrom

Country Status (11)

Country	Link
US (3)	US8361500B2 (zh)
EP (1)	EP2136793B1 (zh)
JP (3)	JP5442459B2 (zh)
AR (1)	AR065802A1 (zh)
CA (1)	CA2681465C (zh)
CL (1)	CL2008000819A1 (zh)
ES (1)	ES2406934T3 (zh)
MX (1)	MX2009010210A (zh)
PE (1)	PE20081891A1 (zh)
TW (1)	TWI350185B (zh)
WO (1)	WO2008118331A2 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030762A1 (es)	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
EP2997964A1 (en)	2006-04-05	2016-03-23	OPKO Health, Inc.	Pharmaceutical formulations comprising salts of (5s,8s)-8-[{(1 r)-1-(3,5-bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one and their medical use
WO2007117486A2 (en)	2006-04-05	2007-10-18	Schering Corporation	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
AU2007264418B2 (en)	2006-06-30	2012-05-03	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
AR066191A1 (es)	2007-03-22	2009-08-05	Schering Corp	Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
PE20081891A1 (es) *	2007-03-22	2008-12-27	Opko Health Inc	Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
JP2011514380A (ja)	2008-03-17	2011-05-06	バイアル−ポルテラアンドシーエー，エス．エー．	５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形
HUE026148T2 (en)	2008-09-05	2016-05-30	Opko Health Inc	8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates
CN102448444B (zh)	2009-04-01	2016-05-25	巴尔-波特拉及康邦亚股份有限公司	包括硝基儿茶酚衍生物的药物制剂及其制备方法
ES2915698T3 (es) *	2009-04-01	2022-06-24	Bial Portela & Ca Sa	Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas
CN104000785B (zh) *	2009-04-24	2021-01-05	伊休蒂卡有限公司	美他沙酮的新剂型
KR20120101285A (ko)	2009-04-24	2012-09-13	아이슈티카 피티와이 리미티드	신규 인도메타신 제제
PH12015501811A1 (en) *	2009-04-24	2019-03-25	Iceutica Pty Ltd	Production of encapsulated nanoparticles at high volume fractions
IL254371B2 (en) *	2009-04-24	2023-09-01	Iceutica Pty Ltd	Production of encapsulated nanoparticles on a commercial scale
NZ595973A (en) *	2009-04-24	2014-02-28	Iceutica Pty Ltd	Production of encapsulated nanoparticles at high volume fractions
JP5906181B2 (ja) *	2009-04-24	2016-04-20	イシューティカピーティーワイリミテッド	商業的ナノ粒子及びマイクロ粒子粉末の生産方法
JO3635B1 (ar) *	2009-05-18	2020-08-27	Millennium Pharm Inc	مركبات صيدلانية صلبة وطرق لانتاجها
ES2609640T3 (es)	2009-08-14	2017-04-21	Opko Health, Inc	Formulaciones intravenosas de rolapitant
GB2475701B (en) *	2009-11-26	2011-10-19	Michael Hilary Burke	A process for the preparation of an orally administered anthelmintic unit dose tablet
US20140045900A1 (en)	2011-02-11	2014-02-13	Bial-Portela & Ca, S.A.	Administration regime for nitrocatechols
US20130303519A1 (en)	2012-03-20	2013-11-14	Millennium Pharmaceuticals, Inc.	Methods of treating cancer using aurora kinase inhibitors
US9452107B2 (en) *	2012-04-16	2016-09-27	New Jersey Institute Of Technology	Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
CA2907726A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
CN106866669A (zh) *	2017-04-19	2017-06-20	成都百特万合医药科技有限公司	一种合成罗拉吡坦中间体的方法
MX2022000816A (es) *	2019-07-19	2022-05-13	Global Alliance For Tb Drug Development Inc	Composiciones de pretomanida.
CN116669715A (zh) *	2020-11-18	2023-08-29	Fb-Hrs有限责任公司	含有多非利特和美西律的组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0812195T3 (da)	1995-02-28	2003-03-03	Aventis Pharma Inc	Farmaceutisk sammensætning til piperidinoalkanolforbindelser
SA99191255B1 (ar) *	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
US6499984B1 (en)	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation
ATE431136T1 (de) *	2000-09-22	2009-05-15	Dainippon Sumitomo Pharma Co	Orale zubereitungen mit vorteilhaften zerfallseigenschaften
PE20030762A1 (es) *	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
NZ538781A (en) *	2002-09-17	2007-11-30	Wyeth Corp	Oral formulations
DE602004010708T2 (de)	2003-10-03	2008-12-04	Pfizer Inc.	Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
KR20060113737A (ko)	2003-12-22	2006-11-02	쉐링 코포레이션	약제학적 조성물
US20070202179A1 (en) *	2004-04-09	2007-08-30	FAULKNER Patrick	Low Dose Pharmaceutical Products
US7354922B2 (en)	2004-12-14	2008-04-08	Schering Corporation	Bridged ring NK1 antagonists
WO2007117486A2 (en)	2006-04-05	2007-10-18	Schering Corporation	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
EP2997964A1 (en) *	2006-04-05	2016-03-23	OPKO Health, Inc.	Pharmaceutical formulations comprising salts of (5s,8s)-8-[{(1 r)-1-(3,5-bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one and their medical use
PE20081891A1 (es)	2007-03-22	2008-12-27	Opko Health Inc	Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas

2008
- 2008-03-19 PE PE2008000515A patent/PE20081891A1/es active IP Right Grant
- 2008-03-19 AR ARP080101153A patent/AR065802A1/es not_active Application Discontinuation
- 2008-03-20 CA CA2681465A patent/CA2681465C/en active Active
- 2008-03-20 ES ES08742155T patent/ES2406934T3/es active Active
- 2008-03-20 US US12/531,966 patent/US8361500B2/en active Active
- 2008-03-20 MX MX2009010210A patent/MX2009010210A/es active IP Right Grant
- 2008-03-20 TW TW097109944A patent/TWI350185B/zh not_active IP Right Cessation
- 2008-03-20 EP EP08742155A patent/EP2136793B1/en active Active
- 2008-03-20 JP JP2009554571A patent/JP5442459B2/ja not_active Expired - Fee Related
- 2008-03-20 WO PCT/US2008/003653 patent/WO2008118331A2/en not_active Ceased
- 2008-03-20 CL CL200800819A patent/CL2008000819A1/es unknown
2013
- 2013-01-04 US US13/734,432 patent/US20130122088A1/en not_active Abandoned
- 2013-07-25 JP JP2013154185A patent/JP5763134B2/ja not_active Expired - Fee Related
2014
- 2014-11-13 US US14/540,635 patent/US20150283121A1/en not_active Abandoned
2015
- 2015-03-09 JP JP2015045534A patent/JP6041919B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8361500B2 (en)	2013-01-29
JP6041919B2 (ja)	2016-12-14
ES2406934T3 (es)	2013-06-10
JP5763134B2 (ja)	2015-08-12
US20150283121A1 (en)	2015-10-08
MX2009010210A (es)	2009-10-19
WO2008118331A3 (en)	2009-04-23
AR065802A1 (es)	2009-07-01
CA2681465A1 (en)	2008-10-02
WO2008118331A2 (en)	2008-10-02
EP2136793B1 (en)	2013-02-20
EP2136793A2 (en)	2009-12-30
JP5442459B2 (ja)	2014-03-12
CL2008000819A1 (es)	2008-09-26
JP2013216694A (ja)	2013-10-24
JP2015108023A (ja)	2015-06-11
CA2681465C (en)	2015-12-15
TW200902087A (en)	2009-01-16
US20100104637A1 (en)	2010-04-29
JP2010522173A (ja)	2010-07-01
US20130122088A1 (en)	2013-05-16
PE20081891A1 (es)	2008-12-27

Publication	Publication Date	Title
TWI350185B (en)	2011-10-11	Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one salts and tablets made therefrom
SG10201500027TA (en)	2015-02-27	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
SG10201500028RA (en)	2015-02-27	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
ZA201000185B (en)	2011-03-30	17beta-cyano-18a-homo-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative
GB2465099B (en)	2010-06-16	Capsule for use with a powder delivery device
EP2040721A4 (en)	2010-03-03	HONEY CONTAINING MEDICAL COMPOSITIONS
EP2056918A4 (en)	2014-01-08	CATHETER FOR ADMINISTERING CELLS
AP2011005549A0 (en)	2011-02-28	Pharmaceutical formulations containing dopamine receptor ligands.
EP2228802A4 (en)	2012-03-07	NUCLEAR REACTOR HOUSING AND LEAK DETECTION LEVEL
IL188444A0 (en)	2008-04-13	Case for accommodating a medicament pack, and use thereof
IL209421A (en)	2015-06-30	Kionoxalindone derivatives, medicines containing them and their use
IL185011A0 (en)	2007-12-03	Tablets with improved drug substance dispersibility
IL204520A0 (en)	2010-11-30	Oxadiazole diaryl compounds, their preparation and pharmaceutical compositions containing them
ZA201102429B (en)	2012-05-30	Novel nitrogenous heterocyclic compounds, preparation thereof and use thereof as antibacterial medicaments
IL206492A (en)	2015-04-30	The heterocyclic spherical cycles and compounds for use as drugs selectively with additional active substance
EP2205218A4 (en)	2010-11-17	ESOMEPRAZOLE-CONTAINING PHARMACEUTICAL COMPOSITION
IL201252A0 (en)	2010-05-31	New nitrogenated heterocyclic compounds, their preparation and use as antibacterial drugs
SI2184279T1 (sl)	2015-04-30	Farmacevtski sestavek, ki vsebuje optično aktivno spojino z aktivnostjo agonista receptorja trombopoetina in njene vmesne spojine
HUE036876T2 (hu)	2018-08-28	4,5-Epoximorfinán származékot tartalmazó stabil tabletta
IL194770A0 (en)	2009-08-03	6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine and its use as a medicament
IL206514A0 (en)	2010-12-30	Triazole oxadiazoles derivatives, their preparation and pharmaceutical compositions containing them
EP2062579A4 (en)	2010-03-03	SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING OPTICALLY STABLE RAMOSETRON
ZA200908962B (en)	2011-02-23	A liquid formulation for administering nicotine
PL2346823T3 (pl)	2016-01-29	Związki pośrednie w syntezie związków 8-[{1-(3,5-bis-(trifluorometylo)fenylo)etoksy}metylo]-8-fenylo-1,7-diaza-spiro[4.5]dekan-2-onu
ZA201000187B (en)	2011-03-30	17b-cyano-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative

Legal Events

Date	Code	Title	Description
2021-07-11	MM4A	Annulment or lapse of patent due to non-payment of fees